1206102-04-6

Basic information

• Product Name: 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one
• Synonyms: 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one
• CAS NO: 1206102-04-6
• Molecular Weight: 322.361
• Mol File: 1206102-04-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one(1206102-04-6)
• EPA Substance Registry System: 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one(1206102-04-6)

Safety Data

• Hazardous Substances Data: 1206102-04-6(Hazardous Substances Data)

Usage

Description

2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one, also known as 3-Benzyloxy-2-(2-hydroxy-2-phenylethyl)-4H-pyran-4-one, is an organic compound that serves as a crucial intermediate in the pharmaceutical industry. It is characterized by its unique chemical structure, which includes a pyran-4-one ring with various substituents that contribute to its reactivity and potential applications.

Uses

Used in Pharmaceutical Industry:
2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one is used as an intermediate in the synthesis of Dolutegravir (D528800), a second-generation HIV-1 integrase strand transfer inhibitor. 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one plays a vital role in the development of antiretroviral drugs, specifically those targeting the integration of the HIV-1 virus into the host genome, thereby inhibiting the replication and spread of the virus.
The compound's unique structure allows it to be a key component in the synthesis of Dolutegravir, which is an essential drug in the treatment of HIV-1 infection. Its presence in the synthesis process contributes to the drug's effectiveness in blocking the integration of the virus into the host's DNA, thus preventing the progression of the disease.

Upstream product

• 118-71-8 Maltol 
• 100-39-0 benzyl bromide 
• 100-52-7 benzaldehyde 
• 61049-69-2 3-O-benzylmaltol 

Downstream Products

• 1206102-05-7 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-pyran-4-one 
• 119736-16-2 3-(benzyloxy)-1-((tert-butoxycarbonyl)amino)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester 
• 1206102-06-8 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid 
• 1206102-07-9 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid methyl ester 
• 1206102-08-0 methyl 1-(2,2-dihydroxyethyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 

Relevant articles and documents

Process optimization of aldol-type reaction by process understanding using in Situ IR

A high-yield robust LHMDS-mediated aldol-type reaction of benzyl maltol (2) and benzaldehyde (3) was developed using in situ IR to overcome the problems of low yield and yield fluctuation of the pilot synthesis. In situ IR studies indicated that unexpecte

Practical and Scalable Synthetic Method for Preparation of Dolutegravir Sodium: Improvement of a Synthetic Route for Large-Scale Synthesis

A practical and scalable synthetic method to obtain dolutegravir sodium (1) was established starting from the readily accessible material maltol (2). This synthetic method includes a scalable oxidation process of maltol and palladium-catalyzed amidation for introduction of an amide moiety, leading to a practical manufacturing method in short synthetic steps. The synthetic method demonstrated herein enables multikilogram scale manufacturing of 1 of high purity.

TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein n, X, Y, Z, R1, R2, and R3 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.